COSTA MESA, Calif., March 30 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) will hold an investor presentation meeting for shareholders, prospective investors and interested parties in Zurich, Switzerland on April 1, 2009. The purpose of the meeting will be to update the investment community on the company's business.
Company chairman and CEO Chris J. Stern will be available to answer shareholder questions along with the co-chairs of the company's medical advisory board, Dr. Bruce D. Spiess, M.D., FAHA - Professor Anesthesiology and Emergency Medicine, VCURES/ VCU Med Center Richmond, Virginia and Dr. Ross Bullock, M.D. Ph.D.- Professor of Neurosurgery,
The three will be in Switzerland in connection with the clinical investigator meeting, a formal initiating step for the Swiss Phase II clinical trial of Oxycyte(R) in traumatic brain injury. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The meeting will be webcast live with the webcast available via the investor relations page of the company website.
Meeting details are as follows: Location: Radisson SAS Zurich Airport Hotel Time: 1:00 p.m. - 3:00 p.m. local time (7:00 a.m. - 9:00 a.m. eastern time) Language: The meeting language will be English
"This will give European investors a chance to participate in a discussion with management and key researchers," said Stern. "We are also planning a meeting of this type in the U.S. later this year."
What: Live webcast of Zurich Investor Meeting When: April 1, 2009 at 1:00 p.m. Zurich time (7:00 a.m. EDT) Where: The live webcast will be available via the investor relations page of the company website at www.Oxybiomed.com or directly at:http://www.videonewswire.com/event.asp?id=57069 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Abe Wischnia of Abe Wischnia & Associates at 619-795-2345
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.
Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from
|SOURCE Oxygen Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved